TrialCancer immunology, immunotherapy : CII2025

Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.

Zhenggang Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.